-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients

Benzinga·09/14/2026 07:52:47
Listen to the news
  • Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill
  • Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis
  • The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027